Market capitalization | $3.29m |
P/E ratio expected | negative |
P/S ratio expected | 0.20 |
EV/Sales expected | 1.11 |
Short interest | 8.81% |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
Dec '23 |
+/-
%
|
||
Turnover | - - |
-
|
|
Gross income | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (operating result) EBIT | - - |
-
|
Net profit | - - |
-
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
DermTech, Inc. is a genomics company in dermatology, which engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate the early detection of skin cancers, assesses inflammatory diseases, and customizes drug treatments. Its products include adhesive skin collection kit, pigmented lesion assay, nevome, and carcinome. The company was founded in 1995 and is headquartered in La Jolla, CA.
Head office | United States |
CEO | Bret Christensen |
Founded | 1995 |
Website | www.dermtech.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.